KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) Leases (2019 - 2025)

Travere Therapeutics (TVTX) has disclosed Leases for 7 consecutive years, with $10.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 26.02% year-over-year to $10.6 million, compared with a TTM value of $10.6 million through Dec 2025, down 26.02%, and an annual FY2025 reading of $10.6 million, down 26.02% over the prior year.
  • Leases was $10.6 million for Q4 2025 at Travere Therapeutics, down from $11.5 million in the prior quarter.
  • Across five years, Leases topped out at $25.0 million in Q1 2021 and bottomed at $10.6 million in Q4 2025.
  • Average Leases over 5 years is $18.6 million, with a median of $19.2 million recorded in 2023.
  • The sharpest move saw Leases plummeted 32.96% in 2021, then fell 9.47% in 2022.
  • Year by year, Leases stood at $23.2 million in 2021, then dropped by 9.47% to $21.0 million in 2022, then decreased by 14.0% to $18.1 million in 2023, then fell by 20.85% to $14.3 million in 2024, then dropped by 26.02% to $10.6 million in 2025.
  • Business Quant data shows Leases for TVTX at $10.6 million in Q4 2025, $11.5 million in Q3 2025, and $12.3 million in Q2 2025.